Sativex
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Background The δ-9-tetrahydrocannabinol-cannabidiol (THC-CBD) oromucosal spray (Sativex) is a standardised cannabinoid based…
OBJECTIVE
Sativex® is an exclusive cannabinoid-based drug approved for the treatment of spasticity due to Multiple Sclerosis (MS…
La sclerose en plaque est une des plus frequentes pathologies neurologiques de l’adulte jeune. Malgre l’avancee fulgurante des…
The therapeutic use of cannabis has generated a lot of interest in the past years, leading to a better understanding of its…
New perspectives in the treatment of Multiple Sclerosis SUMMARY A best knowledge of etiopathogeny and prognosis of Multiple…
Sativex is an oromucosal cannabinoid spray licensed as add‐on therapy for moderate to‐severe spasticity in multiple sclerosis. In…
This article of the month presents results of a clinical study conducted in the UK and Romania, which evaluated the efficacy of a…
764 VOLUME 13 | NUMBER 7 | JULY 2007 NATURE MEDICINE US scientists are waging a campaign urging the government to allow them to…
764 VOLUME 13 | NUMBER 7 | JULY 2007 NATURE MEDICINE US scientists are waging a campaign urging the government to allow them to…
Symptom management in multiple sclerosis (MS) represents a primary focus for neurologists, data available in the literature on…